Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Bayer's gains help European shares hit four-month high

Published 10/13/2017, 05:27 AM
© Reuters. The German share price index, DAX board, is seen at the stock exchange in Frankfurt

By Danilo Masoni

MILAN (Reuters) - European shares hit their highest in nearly four months on Friday, helped by gains in Bayer (DE:BAYGN) after an asset sale deal paving the way for the German drugmaker's $66 billion acquisition of Monsanto (NYSE:MON).

The pan-European STOXX 600 rose 0.3 percent, also underpinned by strength among materials stocks. The index was set for its fifth straight week of gains as inflows into equities continued, with confidence over an economic recovery outweighing rumblings of political risk.

Germany's DAX index was flat, just below the all-time high hit in the previous session, while Britain's FTSE eased back 0.3 percent after a record close on Thursday.

According to EPFR Global data, European equity funds posted solid weekly inflows overall. But Spanish funds suffered their second largest outflow on record and redemptions from Italy climbed to levels last seen in the second quarter of 2015.

Spain's IBEX has lagged over the past two weeks amid concerns over the country's future following an independence referendum in the region of Catalonia declared illegal by authorities in Madrid.

Italy's FTSE MIB has been hit by a sell-off in its banks on worries regulators could impose stricter provisioning rules on bad loans.

On Friday, Bayer gave the biggest boost to the STOXX 600, up 1.6 percent after BASF, the world's third-largest maker of crop chemicals, agreed to buy significant parts of its seed and herbicide businesses for 5.9 billion euros in cash. BASF fell 0.7 percent.

Bayer said it would use the proceeds of the sale to partially refinance the planned acquisition of Monsanto, which it hopes will close in early 2018.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"The recent divestments together with a potential radiology divestment could mean that Bayer only needs a capital raise of below $10 billion which would be a positive surprise," said Baader Helvea analyst Markus Mayer in a note.

Analysts including Mayer said the price paid by BASF was higher than expected but terms of the deal were more favorable compared to market valuation multiples in the same sector.

Bayer is up 19 percent so far this year, against a flat performance for BASF and a 13 percent rise for the DAX.

ACS rose 0.7 percent after sources told Reuters the Spanish builder would launch next week a cash-and-share offer for toll road operator Abertis, complicating a rival bid by Italy's Atlantia.

The offer was expected to be roughly half in cash and the rest in newly issued shares in German construction group Hochtief, which is controlled by ACS, the sources said.

Abertis and Atlantia were flat while Hochtief fell 0.9 percent.

Among top STOXX 600 gainers were Provident Financial, up 18 percent at a six week high. The British subprime lender put in place a recovery plan for its home credit business which it said was set to post a 2017 loss of up to 120 million pounds.

A well-received earnings update boosted shares in Man Group, up 2.8 percent. The British hedge fund said assets rose 7.9 percent in the third quarter, boosted by market gains and net inflows to its funds.

Top faller was British engineering group GKN (LON:GKN) which fell 6.4 percent after a profit warning. The company said full-year profit would come in lower than expected due to disappointing trading in aerospace and two external claims that were expected to cost 40 million pounds.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

I think the pict is wrong here. This pict is from the Catalan Goverment. In the pict Oriol Junqueras, Carles Puigdemont and Anna Gabriel.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.